Picrasidine ICAS# 100234-59-1 |
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 100234-59-1 | SDF | Download SDF |
| PubChem ID | 5324360 | Appearance | Yellow powder |
| Formula | C14H12N2O2 | M.Wt | 240.3 |
| Type of Compound | Alkaloids | Storage | Desiccate at -20°C |
| Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
| Chemical Name | 1-ethenyl-4-methoxy-9H-pyrido[3,4-b]indol-8-ol | ||
| SMILES | COC1=CN=C(C2=C1C3=C(N2)C(=CC=C3)O)C=C | ||
| Standard InChIKey | JOHWQLSNGRWJRK-UHFFFAOYSA-N | ||
| Standard InChI | InChI=1S/C14H12N2O2/c1-3-9-14-12(11(18-2)7-15-9)8-5-4-6-10(17)13(8)16-14/h3-7,16-17H,1H2,2H3 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | Picrasidine I has antiosteoclastogenic effect by inhibiting inflammation induced activation of MAPKs, NF-κB and ROS generation followed by suppressing the gene expression of c-Fos and NFATc1 in osteoclast precursors. |
| Targets | MAPK | NF-κB | ROS | c-Fos | NFATc1 |
| Cell Research | Picrasidine I from Picrasma Quassioides Suppresses Osteoclastogenesis via Inhibition of RANKL Induced Signaling Pathways and Attenuation of ROS Production.[Reference: WebLink]Cellular Physiology & Biochemistry, 2017:1425-1435.Osteoporosis is a metabolic bone disorder that tortures about millions of people worldwide. Recent study demonstrated agents derived from picrasma quassioides is a promising drug for targets multiple signaling pathways. However its potential in treatment of bone loss has not been fully understood. |
Picrasidine I Dilution Calculator
Picrasidine I Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 4.1615 mL | 20.8073 mL | 41.6146 mL | 83.2293 mL | 104.0366 mL |
| 5 mM | 0.8323 mL | 4.1615 mL | 8.3229 mL | 16.6459 mL | 20.8073 mL |
| 10 mM | 0.4161 mL | 2.0807 mL | 4.1615 mL | 8.3229 mL | 10.4037 mL |
| 50 mM | 0.0832 mL | 0.4161 mL | 0.8323 mL | 1.6646 mL | 2.0807 mL |
| 100 mM | 0.0416 mL | 0.2081 mL | 0.4161 mL | 0.8323 mL | 1.0404 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- AMG-208
Catalog No.:BCC1054
CAS No.:1002304-34-8
- Camstatin
Catalog No.:BCC5690
CAS No.:1002295-95-5
- 5,5'-Dimethoxysecoisolariciresinol
Catalog No.:BCN7941
CAS No.:1002106-91-3
- 2,3-dihydroxy-3-(4-hydroxyphenyl)propanoic acid
Catalog No.:BCN1641
CAS No.:100201-57-8
- Piscidinol A
Catalog No.:BCN5818
CAS No.:100198-09-2
- MK-8033
Catalog No.:BCC1768
CAS No.:1001917-37-8
- INH6
Catalog No.:BCC5455
CAS No.:1001753-24-7
- SRT1720 HCl
Catalog No.:BCC2222
CAS No.:1001645-58-4
- BV6
Catalog No.:BCC5372
CAS No.:1001600-56-1
- 1,4,5,6-Tetrahydroxy-7-prenylxanthone
Catalog No.:BCN1642
CAS No.:1001424-68-5
- PDK1 inhibitor
Catalog No.:BCC1843
CAS No.:1001409-50-2
- VUF 8430 dihydrobromide
Catalog No.:BCC7384
CAS No.:100130-32-3
- Picrasidine J
Catalog No.:BCN5820
CAS No.:100234-62-6
- TZ9
Catalog No.:BCC5547
CAS No.:1002789-86-7
- Irinotecan hydrochloride
Catalog No.:BCN2949
CAS No.:100286-90-6
- Apiopaeonoside
Catalog No.:BCN2801
CAS No.:100291-86-9
- Pemirolast potassium
Catalog No.:BCC4532
CAS No.:100299-08-9
- L(+)-Rhamnose monohydrate
Catalog No.:BCN8368
CAS No.:10030-85-0
- Curcumenone
Catalog No.:BCN3008
CAS No.:100347-96-4
- Calcium chloride dihydrate
Catalog No.:BCC7582
CAS No.:10035-04-8
- GSK 1562590 hydrochloride
Catalog No.:BCC8010
CAS No.:1003878-07-6
- Sodium Picosulfate
Catalog No.:BCC4845
CAS No.:10040-45-6
- Danshinspiroketallactone
Catalog No.:BCN3754
CAS No.:100414-80-0
- Lercanidipine
Catalog No.:BCC5239
CAS No.:100427-26-7
Picrasidine I from Picrasma Quassioides Suppresses Osteoclastogenesis via Inhibition of RANKL Induced Signaling Pathways and Attenuation of ROS Production.[Pubmed:29017159]
Cell Physiol Biochem. 2017;43(4):1425-1435.
BACKGROUND/AIMS: Osteoporosis is a metabolic bone disorder that tortures about millions of people worldwide. Recent study demonstrated agents derived from picrasma quassioides is a promising drug for targets multiple signaling pathways. However its potential in treatment of bone loss has not been fully understood. METHODS: The bone marrow macrophages (BMMs) were cultured and induced with M-CSF and RANKL followed by Picrasidine I (PI) treatment. Then the effects of PI on osteoclast formation were evaluated by counting tartrate-resistant acid phosphatase (TRAP)-positive multinucleated cells. Moreover, effects of PI on bone resorption activity of mature osteoclast were studied through bone resorption pit counting and actin ring structure analysis. Further, the involved potential signaling pathways cross-talking were investigated by performed Western blotting and quantitative real-time PCR examination. RESULTS: Results demonstrated PI strongly inhibited RANKL induced osteoclast formation from its precursors. Mechanistically, the inhibitory effect of PI on osteoclast differentiation was due to the suppression of osteoclastogenic transcription factors, c-Fos and NFATc1. Moreover, PI markedly blocked the RANKL-induced osteoclastogenesis by attenuating MAPKs and NF-kappaB signaling pathways. In addition, PI decreased the ROS generation in osteoclast and osteoblast. CONCLUSION: Taken together our data demonstrate that PI has antiosteoclastogenic effect by inhibiting inflammation induced activation of MAPKs, NF-kappaB and ROS generation followed by suppressing the gene expression of c-Fos and NFATc1 in osteoclast precursors.
